Business Wire

ANT-GROUP

Share
Ant Group’s INCLUSION Fintech Conference Debuts in Shanghai

Ant Group, an innovative technology provider, today officially launched its inaugural INCLUSION Fintech Conference, welcoming prominent speakers from all corners of the world, including representatives from the United Nations and the International Monetary Fund, as well as Nobel Prize-winning scholars, to participate in a wide-ranging conversation on how digital technology can help build a more inclusive, green, and sustainable world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005369/en/

Taking place both online and onsite in Shanghai from September 24-26, 2020, the conference brings together thought leaders from across the globe to envision the digital economy of the future. The first day of the conference began with a morning plenary session, followed by 17 forums in the afternoon and a nature-themed music festival along Shanghai’s iconic Huangpu River in the evening.

An offline 13,000sqm exhibition area showcased the latest fintech innovations and technology solutions from Ant Group and Alipay, as well as a variety of other major companies from the technology and financial communities, including Kenyan telecommunications provider Safaricom, Swiss-Thai fintech company Ascend Money, and US financial services company Mastercard.

Key highlights from the first day of the INCLUSION Fintech Conference include:

  • Kristalina Georgieva, Managing Director of the International Monetary Fund (IMF), provided a comprehensive overview of the global economic outlook, highlighting the pivotal role financial inclusion can play in building a better and more resilient world, especially as economies and businesses continue to recover from the COVID-19 pandemic.

IMF Managing Director Kristalina Georgieva delivers keynote speech at inaugural INCLUSION Fintech Conference

“Fintech is already playing an important part in slowing the spread of COVID-19,” emphasized Ms. Georgieva. “It has made contactless and cashless transactions very popular and very useful. Digital financial services also enable governments to quickly expand social safety nets and help facilitate direct payments between people, in turn accelerating economic recovery.”

  • During the plenary session, Eric Jing, Executive Chairman of Ant Group, envisioned a new financial ecosystem that is powered by technological innovation. He stressed that digital technology accelerates the evolution of financial services and makes it more accessible to those in need, bringing equal development opportunities for all.
  • Simon Hu, CEO of Ant Group, emphasized that technology is at the heart of Ant Group’s DNA. “Since our inception over 16 years ago, digital technology has been part and parcel of everything we do, continuously driving the evolution of our strategy, operations, and value proposition.”
  • United Nations Development Progamme Administrator Achim Steiner said: "COVID is accelerating digitization and the dividend could be huge, from helping to deliver our climate goals to improving health and education access. Whether we can actually benefit from the digital transformation, however, depends on how digitalization reshapes finance. The time has come for the financial system to fulfill people’s needs, the ultimate owners of the world’s financial assets – digitalization can fuel that change."
  • Nobel Economics Laureates Michael Spence and Bengt Holmström also shared their views and insights on the current state of global finance and the integration of technology and financial services in a conversation with Long Chen, director of the Luohan Academy, an open-research initiative by Alibaba Group.
  • Forums in the afternoon focused on an array of different topics, including open banking, insurance and technology, and new methods of global remittance, amongst many others.

A full playback of the plenary session will be available on the INCLUSION Fintech Conference’s YouTube channel as well as on the conference’s official website .

About the INCLUSION Fintech Conference

The INCLUSION Fintech Conference was officially announced in January 2020 to bring together the global financial and technology communities, to envision a world that is more inclusive, green, and sustainable through digital technology. The inaugural three-day conference in Shanghai, to be held on September 24-26, 2020, will feature over 40 forums, with keynotes and panels covering major themes such as the global digital economy, digital finance, innovative technology, and sustainability.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye